ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "MEI Pharma, Inc." (MEIP) Report Updated: Nov 24, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"MEI Pharma, Inc." (MEIP)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: ENTA, MACK, BSTC, MDXG

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"MEI Pharma, Inc."© quotemedia

Company Profile

MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited.

Recent News: "MEI Pharma, Inc."